MicroLub raises $10M to replace fat without replacing flavour

MicroLub (Leeds) has raised $10 million (~€8.7 million) led by Northern Gritstone, with existing investor NPIF II – PXN Equity Finance (managed by PXN Ventures as part of the Northern Powerhouse Investment Fund II) also participating. The round, announced 17 September 2026, brings total funding to approximately $14.5 million for the University of Leeds spinout, which is developing protein-based ingredients that replace fats and oils in food products. David Peters, former head of Oatly UK, is CEO.

The ingredient is a biolubricant: a water-based protein system that replicates the physical functions that fat performs in food — lubricity, mouthfeel, texture — without the caloric load. The company reports that manufacturers can reduce fat and calorie content by up to 75% in formulations that use it, while maintaining the sensory experience that drives consumer preference.

What fat actually does in food

Fat is not only a source of calories. It is a functional ingredient: it carries flavour compounds, creates the slippery sensation that reads as richness, stabilises emulsions, and produces the specific texture — creaminess in dairy, crumbliness in biscuits, smoothness in chocolate — that consumers expect from a product. Reformulating without fat means replacing not one thing but several simultaneous functions.

The existing market for fat replacers — polydextrose, inulin, cellulose derivatives, modified starches — has a decades-long history of producing products that consumers find unsatisfying. The compromise between calorie reduction and eating experience is a recognised commercial problem. MicroLub's argument is that protein-based lubrication replicates fat's physical functions more convincingly than carbohydrate-based alternatives, because proteins can be engineered to interact with water in ways that mimic fat's lubricity at the molecular level.

Northern Gritstone, the deep-tech investment fund that backs University of Manchester and University of Leeds spinouts, led MicroLub's earlier £3.5 million seed round in 2024 and is leading again here. The follow-on is a signal that the ingredient performance has held up in the trials that happened between rounds.

Timing and the GLP-1 context

The regulatory and commercial environment for reduced-calorie food formulation has shifted since MicroLub was founded in 2023. GLP-1 receptor agonist drugs (Ozempic, Wegovy) have restructured the weight management market and prompted major food manufacturers to begin reformulating products for consumers who are appetite-suppressed but still want satisfying food. That context makes MicroLub's value proposition easier to explain to procurement teams at large FMCG companies than it would have been two years ago.

The round's stated targets — US and Asian market expansion, trial-to-commercial conversion — are the standard scale-up milestones. The constraint for a food ingredient company is the length of manufacturer qualification and new product development cycles, which typically run two to five years from trial to supermarket shelf. The $10 million gives MicroLub runway to close the commercial agreements that are currently in trial stage, but the revenue will arrive on the manufacturers' timeline, not the investor's.